120 related articles for article (PubMed ID: 35411936)
1. Cyclic-AMP signalling, MYC and hypoxia-inducible factor 1α intersect to regulate angiogenesis in B-cell lymphoma.
Ethiraj P; Sasi B; Holder KN; Lin AP; Qiu Z; Jaafar C; Elkhalili A; Desai P; Saksena A; Ritter JP; Aguiar RCT
Br J Haematol; 2022 Jul; 198(2):349-359. PubMed ID: 35411936
[TBL] [Abstract][Full Text] [Related]
2. A phosphodiesterase 4B-dependent interplay between tumor cells and the microenvironment regulates angiogenesis in B-cell lymphoma.
Suhasini AN; Wang L; Holder KN; Lin AP; Bhatnagar H; Kim SW; Moritz AW; Aguiar RCT
Leukemia; 2016 Mar; 30(3):617-626. PubMed ID: 26503641
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the Myc-PDE4B regulatory circuitry impairs B-cell lymphoma survival.
Nam J; Kim DU; Kim E; Kwak B; Ko MJ; Oh AY; Park BJ; Kim YW; Kim A; Sun H; Jung Y; Lee JH; Shin HJ; Park I; Song DK; Jeong JY; Lee YH; Kim SW
Leukemia; 2019 Dec; 33(12):2912-2923. PubMed ID: 31138843
[TBL] [Abstract][Full Text] [Related]
4. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
Smith PG; Wang F; Wilkinson KN; Savage KJ; Klein U; Neuberg DS; Bollag G; Shipp MA; Aguiar RC
Blood; 2005 Jan; 105(1):308-16. PubMed ID: 15331441
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 4B is an effective therapeutic target in colorectal cancer.
Kim DU; Kwak B; Kim SW
Biochem Biophys Res Commun; 2019 Jan; 508(3):825-831. PubMed ID: 30528730
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.
Pullamsetti SS; Banat GA; Schmall A; Szibor M; Pomagruk D; Hänze J; Kolosionek E; Wilhelm J; Braun T; Grimminger F; Seeger W; Schermuly RT; Savai R
Oncogene; 2013 Feb; 32(9):1121-34. PubMed ID: 22525277
[TBL] [Abstract][Full Text] [Related]
7. Recombinant hirudin suppresses angiogenesis of diffuse large B-cell lymphoma through regulation of the PAR-1-VEGF.
Zhao J; Li Z; Zhang H; Qin T; Zhao J; Pei Q
Chem Biol Drug Des; 2024 May; 103(5):e14533. PubMed ID: 38684373
[TBL] [Abstract][Full Text] [Related]
8. Sphingosine-1-phosphate signalling drives an angiogenic transcriptional programme in diffuse large B cell lymphoma.
Lupino L; Perry T; Margielewska S; Hollows R; Ibrahim M; Care M; Allegood J; Tooze R; Sabbadini R; Reynolds G; Bicknell R; Rudzki Z; Lin Hock Y; Zanetto U; Wei W; Simmons W; Spiegel S; Woodman CBJ; Rowe M; Vrzalikova K; Murray PG
Leukemia; 2019 Dec; 33(12):2884-2897. PubMed ID: 31097785
[TBL] [Abstract][Full Text] [Related]
9. IL-21 Stimulates the expression and activation of cell cycle regulators and promotes cell proliferation in EBV-positive diffuse large B cell lymphoma.
Wang Y; Wang C; Cai X; Mou C; Cui X; Zhang Y; Ge F; Dong H; Hao Y; Cai L; Wu S; Feng C; Chen J; Li J; Xu W; Fan L; Xie W; Tong Y; Gu HF; Wu L
Sci Rep; 2020 Jul; 10(1):12326. PubMed ID: 32704112
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
Szydłowski M; Garbicz F; Jabłońska E; Górniak P; Komar D; Pyrzyńska B; Bojarczuk K; Prochorec-Sobieszek M; Szumera-Ciećkiewicz A; Rymkiewicz G; Cybulska M; Statkiewicz M; Gajewska M; Mikula M; Gołas A; Domagała J; Winiarska M; Graczyk-Jarzynka A; Białopiotrowicz E; Polak A; Barankiewicz J; Puła B; Pawlak M; Nowis D; Golab J; Tomirotti AM; Brzózka K; Pacheco-Blanco M; Kupcova K; Green MR; Havranek O; Chapuy B; Juszczyński P
Cancer Res; 2021 Dec; 81(23):6029-6043. PubMed ID: 34625423
[TBL] [Abstract][Full Text] [Related]
11. The interplay between c-Myc oncogene expression and circulating vascular endothelial growth factor (sVEGF), its antagonist receptor, soluble Flt-1 in diffuse large B cell lymphoma (DLBCL): relationship to patient outcome.
Aref S; Mabed M; Zalata K; Sakrana M; El Askalany H
Leuk Lymphoma; 2004 Mar; 45(3):499-506. PubMed ID: 15160911
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.
Lee JG; Wu R
Neoplasia; 2015 Feb; 17(2):190-200. PubMed ID: 25748238
[TBL] [Abstract][Full Text] [Related]
13. Aggressive B-cell Lymphoma with MYC/TP53 Dual Alterations Displays Distinct Clinicopathobiological Features and Response to Novel Targeted Agents.
Deng M; Xu-Monette ZY; Pham LV; Wang X; Tzankov A; Fang X; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; Hagemeister F; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Liu P; Young KH
Mol Cancer Res; 2021 Feb; 19(2):249-260. PubMed ID: 33154093
[TBL] [Abstract][Full Text] [Related]
14. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.
Zhang J; Sattler M; Tonon G; Grabher C; Lababidi S; Zimmerhackl A; Raab MS; Vallet S; Zhou Y; Cartron MA; Hideshima T; Tai YT; Chauhan D; Anderson KC; Podar K
Cancer Res; 2009 Jun; 69(12):5082-90. PubMed ID: 19509231
[TBL] [Abstract][Full Text] [Related]
15. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
16. Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma.
Kim SW; Rai D; Aguiar RC
Clin Cancer Res; 2011 Nov; 17(21):6723-32. PubMed ID: 21742807
[TBL] [Abstract][Full Text] [Related]
17. Wogonin inhibits multiple myeloma-stimulated angiogenesis via c-Myc/VHL/HIF-1α signaling axis.
Fu R; Chen Y; Wang XP; An T; Tao L; Zhou YX; Huang YJ; Chen BA; Li ZY; You QD; Guo QL; Wu ZQ
Oncotarget; 2016 Feb; 7(5):5715-27. PubMed ID: 26735336
[TBL] [Abstract][Full Text] [Related]
18. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
19. [Impact of PRDM1 gene inactivation on C-MYC regulation in diffuse large B-cell lymphoma].
Zhang XY; Ma ZP; Cui WL; Pang XL; Chen R; Wang L; Zhang W; Li XX
Zhonghua Bing Li Xue Za Zhi; 2018 Jan; 47(1):25-31. PubMed ID: 29325247
[No Abstract] [Full Text] [Related]
20. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
